Amgen Sued for Patent Royalties on Evenity Osteoporosis Drug

Amgen Inc.’s osteoporosis drug Evenity, whose global sales were more than $780 million in 2022, is the target of a lawsuit alleging infringement of three OssiFi-Mab LLC patents whose license Amgen more than a decade ago failed to secure.

Evenity increases bone formation “and, to a lesser extent, decreases bone resorption” by inhibiting the action of sclerostin, which helps to regulate bone metabolism, according to a complaint filed April 21 in the US District Court for the District of Massachusetts. It’s used to treat severe osteoporosis in postmenopausal women at high risk of fracture.

The patents cover methods of increasing ...